ArticleInternal medicine (Tokyo, Japan)2026
Eosinophilic Granulomatosis with Polyangiitis that Manifested after Administration of Benralizumab in a Patient with Refractory Recurrent Bronchial Asthma.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 73-year-old woman with bronchial asthma presented with a rash and peripheral neuropathy. Since 21 years old, her asthma had been treated with glucocorticoids. Benralizumab had been introduced six years ago, and glucocorticoids were discontinued one year later. Bronchial asthma had been in remission for 5 years. On admission, urinalysis findings were mildly abnormal, myeloperoxidase-specific antineutrophil cytoplasmic antibody was positive, and eosinophilia was observed. A renal biopsy showed signs of mild necrotizing vasculitis with eosinophilia. Eosinophilic granulomatosis with polyangiitis (EGPA) was diagnosed. Benralizumab was discontinued, glucocorticoids were restarted, and mepolizumab was administered. Since then, the EGPA and asthma have not recurred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.